Skip to main content
SpringerLink
Log in

Dynamics of Factor XIII Levels After Open Heart Surgery for Congenital Heart Defects: Do Cyanotic and Acyanotic Patients Differ?

  • Original Article
  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

Abstract

Cardiopulmonary bypass (CPB) reduces coagulation factor levels through hemodilution and consumption. Differences in CPB-induced alterations of factor XIII (FXIII) levels in children with cyanotic and acyanotic congenital heart defects (CHDs) are not well characterized. FXIII activity (determined by Berichrom assay), prothrombin index, activated partial thromboplastin time, and fibrinogen were measured before open heart surgery with CPB and 5 days postoperatively for children older than 3 years with acyanotic (n = 30) and cyanotic (n = 30) CHDs. The preoperative FXIII levels did not differ significantly among the children of the compared groups. The cyanotic patients showed a significantly longer duration of CPB (111.4 ± 45.8 vs 71.5 ± 33.6 min; p = 0.026) and aortic cross-clamp (68.0 ± 27.1 vs 45.4 ± 31.4 min; p = 0.034). The drop in FXIII levels after termination of CPB was more profound for the children with cyanotic CHDs (87.1 ± 13.4 to 49.1 ± 13.2 vs 81.5 ± 12.6 to 58.6 ± 11.1 %, respectively; p = 0.018). The cyanotc patients also were restored to their baseline FXIII levels later than the children with acyanotic CHDs (at 48 vs 24 h). The post-CPB dynamics of the majority of the other coagulation parameters in the compared groups of patients were similar. The cyanotic patients experienced significantly greater postoperative blood loss than the acyanotic patients (12.6 ± 4.9 vs 5.0 ± 2.1 mL/kg; p < 0.001) and were transfused with larger volumes of red blood cells (10.4 ± 6.5 vs 4.2 ± 2.5 mL/kg; p = 0.007). The decrease in FXIII levels after CPB is more profound and lasts longer in children with cyanotic CHDs than in acyanotic patients. The rational strategy of postoperative FXIII replacement therapy for these categories of patients needs to be determined.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Attard C, Cini C, Monagle P, Ignjatoic V (2012) The impact of cardiopulmonary bypass on factor XIII levels in children. Thromb Res 130:e238–e239

    Article  CAS  PubMed  Google Scholar 

  2. Bhargava M, Sanyal SK, Thapar MK et al (1976) Impairment of platelet adhesiveness and platelet factor 3 activity in cyanotic congenital heart disease. Acta Hematol 55:216–223

    Article  CAS  Google Scholar 

  3. Blome M, Isgro F, Kiessling AH et al (2005) Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 93:1101–1107

    CAS  PubMed  Google Scholar 

  4. Brodsky I, Gill DN, Lusch CJ (1969) Fibrinolysis in congenital heart disease: preoperative treatment with ε-aminocapronic acid. Am J Clin Pathol 51:51–57

    CAS  PubMed  Google Scholar 

  5. Brody JI, Pickering NJ, Fink GB (1986) Concentrations of factor VIII-related antigen and factor XIII during open heart surgery. Transfusion 26:478–480

    Article  CAS  PubMed  Google Scholar 

  6. Chandler WL, Patel MA, Gravelle L et al (2001) Factor XIIIA and clot strength after cardiopulmonary bypass. Blood Coagul Fibrinolysis 12:101–108

    Article  CAS  PubMed  Google Scholar 

  7. DeLeon SY, LoCicero J, Ilbawi MN, Idriss FS (1986) Repeat median sternotomy in pediatrics: experience in 164 consecutive cases. Ann Thorac Surg 41:184–188

    Article  CAS  PubMed  Google Scholar 

  8. Edmunds LH Jr, Colman RW (2006) Thrombin during cardiopulmonary bypass. Ann Thorac Surg 82:2315–2322

    Article  PubMed  Google Scholar 

  9. Gerlach R, Tölle F, Raabe A, Zimmermann M, Siegemund A, Seifert V (2002) Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: implications of a prospective study. Stroke 33:1618–1623

    Article  PubMed  Google Scholar 

  10. Gertler R, Martin K, Hapfelmeier A, Tassani-Prell P, Braun S, Wiesner G (2013) The perioperative course of factor XIII and associated chest tube drainage in newborn and infants undergoing cardiac surgery. Paediatr Anaesth 23:1035–1041

    Article  PubMed  Google Scholar 

  11. Godje O, Haushofer M, Lamm P, Reichart B (1998) The effect of factor XIII on bleeding in coronary surgery. Thorac Cardiovasc Surg 46:263–267

    Article  CAS  PubMed  Google Scholar 

  12. Godje O, Gallmeier U, Schelian M et al (2006) Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg 54:26–33

    Article  CAS  PubMed  Google Scholar 

  13. Goel M, Dk Shome, Singh ZN et al (2000) Hemostatic changes in children with cyanotic and acyanotic congenital heart disease. Indian Heart J 52:559–563

    CAS  PubMed  Google Scholar 

  14. Goldschmidt B (1970) Effect of vitamin K on clotting factors in children with congenital cyanotic heart disease. Acta Pediatr Acad Sci Hung 11:135–139

    CAS  Google Scholar 

  15. Gralnick HR (1970) ε-Aminocapronic acid in preoperative correction of hemostatic defect in cyanotic congenital heart disease. Lancet 1:1204–1205

    Article  CAS  PubMed  Google Scholar 

  16. Henriksson P, Varendh G, Lundstrom NR (1979) Haemostatic defects in cyanotic congenital heart disease. Br Heart J 41:23–27

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Ihenacho NH, Breeze GR, Fletcher DJ, Stuart J (1973) Consumption coagulopathy in congenital heart disease. Lancet 1:231–234

    Article  CAS  PubMed  Google Scholar 

  18. Karkouti K, von Heymann C, Jespersen CM, Korte W, Levy JH, Ranucci M, Sellke FW, Song HK (2013) Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. J Thorac Cardiovasc Surg 146:927–939

    Article  CAS  PubMed  Google Scholar 

  19. Korte WC, Szadkowski C, Gähler A, Gabi K, Kownacki E, Eder M, Degiacomi P, Zoller N, Devay J, Lange J, Schnider T (2009) Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. Anesthesiology 110:239–245

    CAS  PubMed  Google Scholar 

  20. Levin E, Wu J, Devine DV et al (2000) Hemostatic parameters and platelet activation marker expression in cyanotic and acyanotic pediatric patients undergoing cardiac surgery in the presence of tranexamic acid. Thromb Hemost 83:54–59

    CAS  Google Scholar 

  21. Maurer HM, McCue CM, Robertson LW, Haggins JC (1975) Correction of platelet dysfunction and bleeding in cyanotic congenital heart disease by simple red cell volume reduction. Am J Cardiol 35:831–835

    Article  CAS  PubMed  Google Scholar 

  22. Muszbek L, Adany R, Mikkola H (1996) Novel aspects of blood coagulation factor XIII: I. Structure, distribution, activation, and function. Crit Rev Lab Sci 33:357–421

    Article  CAS  Google Scholar 

  23. Naiman JL (1970) Clotting and bleeding in cyanotic congenital heart disease. J Pediatr 76:333–335

    Article  CAS  PubMed  Google Scholar 

  24. Shainoff JR, Estafanous FG, Yared JP et al (1994) Low factor XIIIa levels are associated with increased blood loss after coronary artery bypass grafting. J Thorac Cardiovasc Surg 108:437–445

    CAS  PubMed  Google Scholar 

  25. Ternström L, Radulovic V, Karlsson M, Baghaei F, Hyllner M, Bylock A, Hansson KM, Jeppsson A (2010) Plasma activity of individual coagulation factors, hemodilution and blood loss after cardiac surgery: a prospective observational study. Thromb Res 126:e128–e133

    Article  PubMed  Google Scholar 

  26. Wedemeyer AL, Edson JR, Krivit W (1972) Coagulation in cyanotic congenital heart disease. Am J Dis Child 124:656–660

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was funded by Novo Nordisk, Inc. and from the budget of the Bakoulev Center for Cardiovascular Surgery. Sergey B. Zaets and Eva H. N. Olsen are employees of Novo Nordisk, Inc.

Author information

Authors and Affiliations

  1. Bakoulev Center for Cardiovascular Surgery, Moscow, Russia

    Leo A. Bockeria, Natalia N. Samsonova, Ivan A. Yurlov, Ludmila G. Klimovich & Elena F. Kozar

  2. Novo Nordisk, Inc., 800 Scudders Mill Road, Princeton, NJ, 085536, USA

    Eva H. N. Olsen & Sergey B. Zaets

Authors
  1. Leo A. Bockeria
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natalia N. Samsonova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ivan A. Yurlov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ludmila G. Klimovich
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elena F. Kozar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eva H. N. Olsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sergey B. Zaets
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sergey B. Zaets.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bockeria, L.A., Samsonova, N.N., Yurlov, I.A. et al. Dynamics of Factor XIII Levels After Open Heart Surgery for Congenital Heart Defects: Do Cyanotic and Acyanotic Patients Differ?. Pediatr Cardiol 35, 1108–1115 (2014). https://doi.org/10.1007/s00246-014-0903-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-014-0903-9

Keywords

Search

Navigation